{"id":"NCT01729754","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","officialTitle":"A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-05","primaryCompletion":"2015-09-28","completion":"2021-10-26","firstPosted":"2012-11-20","resultsPosted":"2018-06-27","lastUpdate":"2022-03-08"},"enrollment":1090,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Tildrakizumab 200 mg","otherNames":["SCH 900222, MK-3222"]},{"type":"DRUG","name":"Tildrakizumab 100 mg","otherNames":["SCH 900222, MK-3222"]},{"type":"DRUG","name":"Tildrakizumab Placebo","otherNames":[]},{"type":"DRUG","name":"Etanercept Placebo","otherNames":[]},{"type":"DRUG","name":"Etanercept 50 mg","otherNames":["Embrel"]}],"arms":[{"label":"Tildrakizumab 200 mg","type":"EXPERIMENTAL"},{"label":"Tildrakizumab 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Etanercept 50 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis. The primary hypotheses of the study are that tildrakizumab is superior to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of participants achieving \\>= Psoriasis Area Sensitivity Index of 75% (PASI-75) response and the proportion of participants with a Physician's Global Assessment (PGA) score of \"clear\" or \"minimal\" with at least a 2 grade reduction from baseline at Week 12.","primaryOutcome":{"measure":"Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1)","timeFrame":"Week 12","effectByArm":[{"arm":"Tildrakizumab 200 mg","deltaMin":65.6,"sd":null},{"arm":"Tildrakizumab 100 mg","deltaMin":61.2,"sd":null},{"arm":"Placebo","deltaMin":5.8,"sd":null},{"arm":"Etanercept 50 mg","deltaMin":48.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28596043","40365708","36098877","33544883","32162721","31268369","31218661","30915660"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":527},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Arthralgia","Injection site erythema"]}}